Atai Life Sciences N.V. (ATAI) News & Overview - Discounting Cash Flows
ATAI
Atai Life Sciences N.V.
ATAI (NASDAQ)

ATAI's Business Model

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Sector & Industry Healthcare / Biotechnology
Website https://www.atai.life
CEO (Chief Executive Officer) Srinivas G. Rao
Number of Employees
IPO date June 18, 2021

ATAI Latest News

Contact
CountryDE
AddressKrausenstrasse 9-10
CityBerlin
StateNone
Phone49 89 2153 9035
Zip Code10117
Other Identifiers
CIK0001840904
ISINNL0015000DX5
CUSIPN0731H103
Open2.79
Previous Close2.75
Volume4.12 Mil.
Average Volume3.13 Mil.
Day’s Range2.62 – 2.8
52 Week Range1.03-2.96
MA (50)1.9578
MA (200)1.5861
Market Cap556.1 Mil.
Shares Out.200.8 Mil.
Earnings DateAug 11, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for ATAI

Company
Market Cap
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us